Back to overview

What’s new in prostate cancer?

Here’s a preview of hot topics that are included in the scientific programme at EAU24 for prostate cancer (PCa), including two Plenary Sessions you don’t want to miss!

  • Risk-adapted screening and treatment of screen-detected PCa: A review of evolving screening strategies, risk group management, and the efficacy of current and future screening methods. Major trials like PROSCREEN and PROBASE will be discussed. Chairs: Prof. Peter Albers (DE) and Prof. Arnauld Villers (FR), Saturday 6 April, 08:00 – 10:00 CEST
  • Personalised approaches in high-risk and metastatic PCa: Details the tailoring of treatments based on morphological and genomic features, interpreting PSMA-PET scans optimally, and debating the omission of PLND. Discussions extend to personalised treatments for biochemical relapse and metastatic disease, including PARP inhibitor use in mCRPC. Chairs: Prof. Silke Gillessen (CH) and Prof. Alberto Briganti, Milan (IT), Sunday 7 April, 08:00 – 10:00 CEST

More sessions on prostate cancer at EAU24:

See the full EAU24 scientific programme for more details.

Last chance to get the special rates! – The late registration discount ends on 4 March 2024 (23:59 CET). After this date, you can still register, but with the regular fees.